<DOC>
	<DOCNO>NCT00611663</DOCNO>
	<brief_summary>The aim study compare immunological efficacy two pneumococcal vaccination strategy patient systemic lupus erythematosus ( SLE ) treat corticosteroid associate immunosuppressive drug : 1 ) prime-boost strategy use vaccination conjugate vaccine ( Prevenar® ) week 0 Poly Saccharidic vaccine ( Pneumo23® ) 6 month ( W24 ) 2 ) compare standard vaccination Poly Saccharidic vaccine ( Pneumo23® ) W24 placebo W0</brief_summary>
	<brief_title>Safety Study Two Vaccine Strategies Patients With Systemic Lupus Erythematosus</brief_title>
	<detailed_description>Infections frequent potentially serious patient SLE compare healthy subject . This risk increase patient treated corticosteroid and/or immunosuppressive drugs.Among serious infection happen context , respiratory infection among frequent Streptococcus pneumoniae one often responsible germs.Although specific study SLE , finding indicate patient SLE could benefit preventive vaccination pneumococcal infections.Two pneumococcal vaccine available : Pneumo23® , Poly Saccharidic vaccine indicate adult child &gt; 2 year risk pneumococcal infection ; Prevenar® , conjugate vaccine , indicate child &lt; 2 years.Pneumo23® find safe SLE le immunogenic general population.Prevenar® already study immunocompromised patient ( HIV-infected patient , patient renal transplantation ) . It show immunological efficacy well Prevenar® administrate prior Pneumo23® , compare Pneumo23® administrate alone.To knowledge , prime-boost strategy assess patient SLEThe primary objective study compare immunological efficacy two pneumococcal vaccination strategy patient systemic lupus erythematosus ( SLE ) treat corticosteroid associate immunosuppressive drug : 1 ) Vaccination conjugate vaccine ( Prevenar® ) week 0 Poly Saccharidic vaccine ( Pneumo23® ) 6 month ( W24 ) 2 ) Vaccination placebo W0 Poly Saccharidic vaccine ( Pneumo23® ) W24Secondary objective : - To compare clinical biological tolerance two vaccinal strategies· - To evaluate durability sero protection 6 24 month vaccination Pneumo23® - To search predictive factor determinant pneumococcal vaccine response</detailed_description>
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>age 18 65 year SLE define ACR classification Stable SLE ( treatment modify 2 month precede inclusion date W0 ) SLE treat immunosuppressant systemic corticosteroid dose ≥ 5 mg/j systemic corticosteroid dose associate one immunosuppressive drug SLE treat hydroxychloroquine 31 month follow female must effective method contraception first 7 month study negative serum urinary pregnancy test female wish child 7 month follow W0 physical examination sign write informed consent pregnant female female wish child 7 month follow W0 subject infect HIV and/or HBV ( Ag HBs+ ) HVC medical history allergy vaccine component receipt pneumococcal vaccine le 5 year receipt vaccine within one month prior enrolment ( inclusion visit W0 ) receipt immunoglobulin within three month prior enrolment ( inclusion visit W0 ) splenectomy hematopoietic disorder give contraindication intramuscular hypodermic route injection , active malignancy , cirrhosis intercurrent illness within one month prior enrolment ( inclusion visit W0 ) patient biotherapy ( antiCD20 ) must include interval vaccination end biotherapy less one year . participation another clinical study first 7 month study subject cover Health Insurance</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Pneumococcal vaccine</keyword>
	<keyword>SLE</keyword>
	<keyword>Vaccination</keyword>
	<keyword>Immunosuppression</keyword>
	<keyword>SLE define ACR classification</keyword>
	<keyword>Stable SLE</keyword>
	<keyword>SLE treat systemic corticosteroid</keyword>
</DOC>